NCT07791654|CompletedPhase 2
Loading search results
Sponsor study identifier
interventional
120
1 country
1
Study Start
August 23, 2025
Actual (reported)Primary Completion
March 21, 2026
Actual (reported)Study Completion
March 21, 2026
Actual (reported)This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity. A total of 120 participants were enrolled in the study. All participants were randomly assigned using stratified block randomization by gender (male or female) and allocated to 4 treatment groups at a 1:1:1:1 ratio, with approximately 30 participants in each group. Each treatment group will reach the This study consists of a screening period of up to 2 weeks, a treatment period of 24 weeks, and a follow-up period of 2 weeks, totaling 28 weeks. The primary endpoint is the percentage change in body weight compared to the baseline after 24 weeks of drug administration. The secondary endpoints include the proportions of participants with a body weight reduction of ≥5%, ≥10%, ≥15%, and ≥20% relative to the baseline after 24 weeks of treatment, as well as the change in waist circumference relative to the baseline.target dose through dose titration.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 21, 2026
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 23, 2025
Actual (reported)March 21, 2026
Actual (reported)March 21, 2026
Actual (reported)August 24, 2026
Actual (reported)August 28, 2026
Actual (reported)Percentage change in body weight compared to baseline after 24 weeks of drug administration
Percentage change in body weight from baseline to Week 24.
Baseline, Week 24
Change in body weight from baseline over time
Baseline, Week 24
Proportion of Participants Achieving ≥5% Body Weight Reduction from Baseline at Week 24
Baseline, Week 24
Proportion of Participants Achieving ≥10% Body Weight Reduction from Baseline at Week 24
Baseline, Week 24
Proportion of Participants Achieving ≥15% Body Weight Reduction from Baseline at Week 24
Baseline, Week 24
Proportion of Participants Achieving ≥20% Body Weight Reduction from Baseline at Week 24
Baseline, Week 24
Administered SC, QW, 24 weeks
Administered SC, QW, 24 weeks
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
120 participants (actual enrollment reported by the registry).
First Submitted
August 24, 2026
First Posted
August 28, 2026
Study Start
August 23, 2025
Actual (reported)Administered SC, QW, 24 weeks
Administered SC, QW, 24 weeks
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 21, 2026
Actual (reported)Study Completion
March 21, 2026
Actual (reported)Last Updated
August 28, 2026
Record last verified: 2026-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: